|
|
|
|
DuPont to expand Pioneer Hi-Bred plant genetics research facilities in Iowa
DES MOINES -- DuPont announced plans to expand its cutting-edge plant genetics research to help farmers increase agricultural productivity.DuPont business Pioneer Hi-Bred will expand its presence in central Iowa with additional lab facilities and jobs...
|
|
|
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
TOKYO, March 19 /PRNewswire/ -- Astellas Pharma Inc.(TSE: 4503) today notified OSI Pharmaceuticals Inc. (Nasdaq: OSIP) that John D. Gilly, Ph. and Margaret T. Monaco will replace Jack Kaye and Heidi L. Steiger on the slate of directors Astellas...
|
|
|
Surgery Beats Radiation for Cervical Carcinoma, but More Research Still Needed: Presented at SGO
my personal edition> cervical cancer > news E-Mail this DGDispatch to a colleague DGDispatch SAN FRANCISCO -- March 20, 2010 -- A retrospective analysis suggests a change in treatment for women with stage IB2 cervical carcinoma.The...
|
|
|
High Inoculum Pseudomonas aeruginosa Attenuates Colistin Bactericidal Activity Characterized by a New Mechanism-based Population Pharmacodynamic Model [Article]
High Inoculum Pseudomonas aeruginosa Attenuates Colistin Bactericidal Activity Characterized by a New Mechanism-based Population Pharmacodynamic Model Jrgen B.Bulitta*, Jenny C. Yang, Liliana Yohonn, Neang S. Ly, Silvia V. Brown, Rebecca E....
|
|
|
In vitro and in vivo activity of 1,3,4-thiadiazole-2-arylhydrazone derivatives of megazol on Trypanosoma cruzi [Article]
In vitro and in vivo activity of 1,3,4-thiadiazole-2-arylhydrazone derivatives of megazol on Trypanosoma cruzi K.Salomo, E. de Souza, S. Carvalho, E. da Silva, C. Fraga, H. Barbosa, and S. de Castro* Laboratrio de Biologia Celular,...
|
|
|
Immunologic analysis and serum heavy metal levels in exacerbated Tourette syndrome
Hsieh M-Y, Lee W-I, Lin K-L, Hung P-C, Chou M-L, Chang M-Y, Huang J-L, Wang H-S.Pediatr Allergy Immunol 2010. 2010 John Wiley & Sons A/S Tourette syndrome (TS) is a childhood-onset and relapsing disorder characterized by involuntary simple or complex...
|
|
|
FDA: High-Dose Simvastatin Given With Certain Drugs Increases Risk of Myopathy
my personal edition> cholesterol/lipid disorders > news E-Mail this DGNews to a colleague DGNews ROCKVILLE, Md -- March 19, 2010 -- Based on review of data from a large clinical trial and data from other sources, the US Food and Drug...
|
|
|
Cetuximab Active, Tolerated in Advanced Endometrial Cancer: Presented at SGO
my personal edition> uterine cancer > news E-Mail this DGDispatch to a colleague DGDispatch SAN FRANCISCO -- March 19, 2010 -- Clinicians may have a new agent for patients with progressive or recurrent endometrial cancer.New data show...
|
|
|
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
58.94 0.24 0.41% Enter Symbols: Sponsored by: TOKYO, March 19 /PRNewswire/ -- Astellas Pharma Inc.(TSE: 4503) today notified OSI Pharmaceuticals Inc. (Nasdaq: OSIP) that John D. Gilly, Ph. and Margaret T. Monaco will replace Jack Kaye and Heidi L.
|
|
|
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
TOKYO, March 19 /PRNewswire/ -- Astellas Pharma Inc.today notified OSI Pharmaceuticals Inc. ( NASDAQ:OSIP) that John D. Gilly, Ph. and Margaret T. Monaco will replace Jack Kaye and Heidi L. Steiger on the slate of directors Astellas plans to...
|
|
|
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
Astellas Pharma Inc.(TSE: 4503) today notified OSI Pharmaceuticals Inc. (Nasdaq: OSIP) that John D. Gilly, Ph.D. and Margaret T. Monaco will replace Jack Kaye and Heidi L. Steiger on the slate of directors Astellas plans to nominate for election to...
|
|
|
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
Astellas Pharma Inc.(TSE: 4503) today notified OSI Pharmaceuticals Inc. (Nasdaq: OSIP) that John D. Gilly, Ph.D. and Margaret T. Monaco will replace Jack Kaye and Heidi L. Steiger on the slate of directors Astellas plans to nominate for election to...
|
|
|
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
Astellas Pharma Inc.(TSE: 4503) today notified OSI Pharmaceuticals Inc. (Nasdaq: OSIP) that John D. Gilly, Ph.D. and Margaret T. Monaco will replace Jack Kaye and Heidi L. Steiger on the slate of directors Astellas plans to nominate for election to...
|
|
|
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
Astellas Pharma Inc.(TSE: 4503) today notified OSI Pharmaceuticals Inc. (Nasdaq: OSIP) that John D. Gilly, Ph.D. and Margaret T. Monaco will replace Jack Kaye and Heidi L. Steiger on the slate of directors Astellas plans to nominate for election to...
|
|
|
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
Astellas Pharma Inc.(TSE: 4503) today notified OSI Pharmaceuticals Inc. (Nasdaq: OSIP) that John D. Gilly, Ph.D. and Margaret T. Monaco will replace Jack Kaye and Heidi L. Steiger on the slate of directors Astellas plans to nominate for election to...
|
|
|
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
TOKYO, March 19 /PRNewswire/ -- Astellas Pharma Inc.(TSE: 4503) today notified OSI Pharmaceuticals Inc. (Nasdaq: OSIP) that John D. Gilly, Ph.D. and Margaret T. Monaco will replace Jack Kaye and Heidi L. Steiger on the slate of directors Astellas...
|
|
|
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
Astellas Pharma Inc.(TSE: 4503) today notified OSI Pharmaceuticals Inc. (Nasdaq: OSIP) that John D. Gilly, Ph.D. and Margaret T. Monaco will replace Jack Kaye and Heidi L. Steiger on the slate of directors Astellas plans to nominate for election to...
|
|
|
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Direct
TOKYO, March 19 /PRNewswire/ -- Astellas Pharma Inc.Astellas is committed to providing an independent voice for OSI stockholders who want its board of directors to consider Astellas' compelling $52 per share all-cash offer for OSI. Gilly currently serves...
|
|
|
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
TOKYO, March 19 /PRNewswire/ -- Astellas Pharma Inc.(TSE: 4503) today notified OSI Pharmaceuticals Inc. (Nasdaq: OSIP) that John D. Gilly, Ph.D. and Margaret T. Monaco will replace Jack Kaye and Heidi L. Steiger on the slate of directors Astellas...
|
|
|
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
Astellas Pharma Inc.(TSE: 4503) today notified OSI Pharmaceuticals Inc. (Nasdaq: OSIP) that John D. Gilly, Ph.D. and Margaret T. Monaco will replace Jack Kaye and Heidi L. Steiger on the slate of directors Astellas plans to nominate for election to...
|
|
|
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
Astellas Pharma Inc.(TSE: 4503) today notified OSI Pharmaceuticals Inc. (Nasdaq: OSIP) that John D. Gilly, Ph.D. and Margaret T. Monaco will replace Jack Kaye and Heidi L. Steiger on the slate of directors Astellas plans to nominate for election to...
|
|
|
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
TOKYO, March 19 /PRNewswire/ -- Astellas Pharma Inc.(TSE: 4503) today notified OSI Pharmaceuticals Inc. (Nasdaq: OSIP) that John D. Gilly, Ph.D. and Margaret T. Monaco will replace Jack Kaye and Heidi L. Steiger on the slate of directors Astellas...
|
|
|
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
Astellas Pharma Inc.(TSE: 4503) today notified OSI Pharmaceuticals Inc. (Nasdaq: OSIP) that John D. Gilly, Ph.D. and Margaret T. Monaco will replace Jack Kaye and Heidi L. Steiger on the slate of directors Astellas plans to nominate for election to...
|
|
|
Alzheimers Disease: Another Promising Drug Bites the Dust
A recent article on Alzheimers disease (AD) reviews the pathogenesis of this increasingly common disorder.1 Various agents are in development which have potential for arresting the disease process and perhaps improve the progressive cognitive decline which is...
|
|
|
Regulus Announces U.S. Allowance of Stanford Patent Application Covering miR-181a Function in Immune Cells
Patent News Breaking News News source: Business Wire Regulus Therapeutics Inc.announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR...
|
